Patient ID: 0000

Specimen ID: **087-146-1940-0** 

DOB: **05/25/1981** 

Age: 43
Sex: Female

#### **Patient Report**

Account Number: **31002080**Ordering Physician: **D BARAD** 



Date Collected: **03/28/2025** Date Received: **03/28/2025** 

Date Reported: **04/10/2025** 

Fasting: No

Ordered Items: Natural Killer Cell Surface Ag; Anti-Annexin V IgG,IgM; Anti-PS/PT Abs IgG, IgM; Factor V Leiden Mutation; Antiparietal Cell Antibody; Rheumatoid Factor (RF); Intrinsic Factor Abs, Serum; Antigliadin Abs, IgA; Protein S-Functional; t-Transglutaminase (tTG) IgA; Anti-CCP Ab, IgG + IgA (RDL); Sedimentation Rate-Westergren; Drawing Fee

#### **General Comments & Additional Information**

A courtesy copy of this report has been sent to 2129944499.

Date Collected: 03/28/2025

# Natural Killer Cell Surface Ag

Test	Current Resu	ılt and Flag	Previous Re	sult and Date	Units	Reference Interval
Ab NK (CD56/16) <sup>A</sup>	135				/uL	24-406
% NK (CD56/16) A, 01	5.4				%	1.4-19.4
WBC <sup>B, 02</sup>	6.9		5.8	10/17/2024	x10E3/uL	3.4-10.8
RBC B, 02	4.00		4.45	10/17/2024	x10E6/uL	3.77-5.28
Hemoglobin <sup>B, 02</sup>	12.9		14.0	10/17/2024	g/dL	11.1-15.9
Hematocrit <sup>B, 02</sup>	39.0		43.9	10/17/2024	%	34.0-46.6
▲ MCV <sup>B, 02</sup>	98	High	99	10/17/2024	fL	79-97
MCH B, 02	32.3		31.5	10/17/2024	pg	26.6-33.0
MCHC B, 02	33.1		31.9	10/17/2024	g/dL	31.5-35.7
RDW <sup>B, 02</sup>	11.9		12.0	10/17/2024	%	11.7-15.4
Platelets B, 02	350		382	10/17/2024	x10E3/uL	150-450
Neutrophils B, 02	57		52	10/17/2024	%	Not Estab.
Lymphs B, 02	36		38	10/17/2024	%	Not Estab.
Monocytes B, 02	5		7	10/17/2024	%	Not Estab.
Eos B, 02	1		2	10/17/2024	%	Not Estab.
Basos B, 02	1		1	10/17/2024	%	Not Estab.
Neutrophils (Absolute) B, 02	3.9		3.0	10/17/2024	x10E3/uL	1.4-7.0
Lymphs (Absolute) B, 02	2.5		2.2	10/17/2024	x10E3/uL	0.7-3.1
Monocytes(Absolute) B, 02	0.4		0.4	10/17/2024	x10E3/uL	0.1-0.9
Eos (Absolute) <sup>B, 02</sup>	0.1		0.1	10/17/2024	x10E3/uL	0.0-0.4
Baso (Absolute) B, 02	0.1		0.1	10/17/2024	x10E3/uL	0.0-0.2
Immature Granulocytes B, 02	0		0	10/17/2024	%	Not Estab.
Immature Grans (Abs) B, 02	0.0		0.0	10/17/2024	x10E3/uL	0.0-0.1

#### Anti-Annexin V IgG, IgM

Test Current Result and Flag Previous Result and Date Units Reference Interval

Anti-Annexin V IgG\*\* C.03 S AU/mL

Reference Range:

<10

\*\*Results of this test are for research purposes only per the assay manufacturer. The performance characteristics of this assay have not been established. The result should not be used as a diagnostic procedure without confirmation of

labcorp

Date Created and Stored  $\,04/10/25\,2005\,ET\,$  Final Report  $\,$  Page 1 of 5

Patient ID: 0000

Specimen ID: **087-146-1940-0** 

### DOB: **05/25/1981**

Age: 43
Sex: Female

#### **Patient Report**

Account Number: **31002080**Ordering Physician: **D BARAD** 



Date Collected: 03/28/2025

AU/mL

# Anti-Annexin V IgG, IgM (Cont.)

the diagnosis by another medically established diagnostic product or procedure.

Anti-Annexin V IgM\*\* C, 03 <5 Reference Range:

<18

\*\*Results of this test are for research purposes only per the assay manufacturer. The performance characteristics of this assay have not been established. The result should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

# Anti-PS/PT Abs IgG, IgM

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Anti-PS/PT Abs IgG <sup>C, 03</sup>	<10		Units	
	Reference Range: <31			
Anti-PS/PT Abs IgM <sup>c, 03</sup>	27		Units	
-	Reference Range: <31			

#### **Factor V Leiden Mutation**

lest	Current Result and Flag	Previous Result and Date	Units	Reference Interval

Factor V Leiden C, 03

Result: Negative (no mutation found)

Factor V Leiden is a specific mutation (R506Q) in the factor V gene that is associated with an increased risk of venous thrombosis. Factor V Leiden is more resistant to inactivation by activated protein C. As a result, factor V persists in the circulation, leading to a mildly hypercoagulable state. The Factor V Leiden mutation accounts for 90% - 95% of APC resistance. Factor V Leiden has been reported in patients with deep vein thrombosis, pulmonary embolus, central retinal vein occlusion, cerebral sinus thrombosis and hepatic vein thrombosis. Other risk factors to be considered in the workup for venous thrombosis include the G20210A mutation in the factor II (prothrombin) gene, protein S and C deficiency, and antithrombin deficiencies. Anticardiolipin antibody and lupus anticoagulant analysis may be appropriate for certain patients, as well as homocysteine levels. Contact your local Labcorp for information on how to order additional testing, if desired.

#### Methodology:

DNA analysis of the Factor V gene is performed by allele-specific PCR. The analytical sensitivity and specificity are both >99%. Molecular-based testing is highly accurate but, as for any laboratory test, analytical errors may occur. All test results must be combined with clinical information for the most accurate interpretation.

labcorp

Date Created and Stored 04/10/252005 ET Final Report Page 2 of 5

Patient ID: 0000

Specimen ID: **087-146-1940-0** 

DOB: **05/25/1981** 

Age: **43** Sex: **Female** 

# **Patient Report**

Account Number: **31002080** Ordering Physician: **D BARAD** 



Date Collected: 03/28/2025

# **Factor V Leiden Mutation (Cont.)**

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

#### References:

Zhang S et al. Genet Med 2018; 20(12): 1489-1498. Bhatt S et al. Genet Med 2021; 23:2463.

Voelkerding K Clin Lab Med 1996; 16:169-186.

### **Antiparietal Cell Antibody**

Test	Current Re	sult and Flag	Previous Result and Date	Units	Reference Interval
Antiparietal Cell Antibody D, 04	1.6			Units	0.0-20.0
			Negative	0.0 - 20.0	
			Equivocal	20.1 - 24.9	
			Positive	>24.9	
		Parietal Cell	Antibodies are found in 90%	of patients	
	with pernicious anemia and 30% of first degree relatives with pernicious anemia.				

# **Rheumatoid Factor (RF)**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Rheumatoid Factor (RF) B, 02	<10.0		IU/mL	<14.0

# **Intrinsic Factor Abs, Serum**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Intrinsic Factor Abs, Serum D, 04	0.9		AU/mL	0.0-1.1

# Antigliadin Abs, IgA

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Deamidated Gliadin Abs, IgA A, 04	5		units	0-19
		Negative	0 - 19	
		Weak Positive	20 - 30	
		Moderate to Strong Po	sitive >30	

#### **Protein S-Functional**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Protein S-Functional E, 05	73		%	63-140
	result) in patients receivin apixaban, edoxaban) or a dir	lsely increased (masking an a g direct Xa inhibitor (e.g., ect thrombin inhibitor (e.g., to assay interference by thes	rivaroxaban, dabigatran)	

# t-Transglutaminase (tTG) IgA

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
t-Transglutaminase (tTG) IgA <sup>F,</sup>	<sup>04</sup> <2		U/mL	0-3
		Negative	0 - 3	
		Weak Positive	4 - 10	

# labcorp

Patient ID: 0000

Specimen ID: **087-146-1940-0** 

DOB: 05/25/1981

Age: 43
Sex: Female

#### **Patient Report**

Account Number: **31002080**Ordering Physician: **D BARAD** 



Date Collected: **03/28/2025** 

# t-Transglutaminase (tTG) IgA (Cont.)

Positive

>10

Tissue Transglutaminase (tTG) has been identified as the endomysial antigen. Studies have demonstrated that endomysial IgA antibodies have over 99% specificity for gluten sensitive enteropathy.

# Anti-CCP Ab, IgG + IgA (RDL)

Test	Current Result	and Flag	Previous Resul	lt and Date	Units	Reference Interval
Anti-CCP Ab, IgG + IgA (RDL) E, 06	<20				Units	<20
		Negative:	<20	Weak Positiv	re: 20-39	
		Moderate	Positive: 40-59	Strong Posit	ive: >59	

### **Sedimentation Rate-Westergren**

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Sedimentation				
Rate-Westergren B, 02	6		mm/hr	0-32

#### Disclaimer

The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

#### Icon Legend

#### **Test Report Date**

A: 03/31/2025

B: 03/29/2025

C: 04/10/2025

D: 03/30/2025

E: 04/02/2025

F: 04/01/2025

# Performing Labs

01: DA - Labcorp Dallas, 7777 Forest Ln Bldg C350, Dallas, TX 75230-2544 Dir: Celeste Vardaman, MD

02: JAYKS - Labcorp Overland Park, 7800 West 110th Street, Overland Park, KS 66210-2304 Dir: Spencer Kerley, MD

03: UY - Esoterix Inc, 8490 Upland Drive Ste 100, Englewood, CO 80112-7116 Dir: Brian F. Poirier, MD

04: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD

05: CETWE - Labcorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 Dir: Earle Collum, MD

06: ESECF - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD

For inquiries, the physician may contact Branch: 800-631-5250 Lab: 913-338-4070

Patient ID: 0000

Specimen ID: **087-146-1940-0** 

DOB: **05/25/1981** 

Age: **43** Sex: **Female**  **Patient Report** 

Account Number: **31002080** Ordering Physician: **D BARAD** 



Patient Details
Fisher, Naomi J
2733 E GLENWOOD ST, SPRINGFIELD, MO,
65804

Phone: **417-459-8145**Date of Birth: **05/25/1981** 

Age: **43**Sex: **Female**Patient ID: **0000**Alternate Patient ID:

Physician Details

**D BARAD** 

Center For Human Reproduction 21 E 69TH ST, NEW YORK, NY, 10021

Phone: **212-994-4400** Account Number: **31002080** 

Physician ID: **0000** NPI: **1508959628**  Specimen Details

Specimen ID: **087-146-1940-0** Control ID: **52086546361** Alternate Control Number:

Date Collected: 03/28/2025 1344 Local
Date Received: 03/28/2025 0000 ET
Date Entered: 03/28/2025 1721 ET
Date Reported: 04/10/2025 2005 ET